Credit: Sheheryar Kabraji, Sridhar Ramaswamy
Recently presented at the American Association for Cancer Research (AACR) Annual Meeting (Atlanta, GA, USA, 29 March–3 April 2019); a Phase I clinical trial and US FDA expanded access program investigated LOXO-195, a next-generation TRK inhibitor designed to block TRK activity in acquired NTRK resistance mutation tumors.